Future Trends & Employer Readiness
Pipeline intelligence, regulatory outlook, CMS policy developments, genomic compliance, and comprehensive readiness checklists for benefits professionals.
The cell and gene therapy (CGT) landscape is entering its most consequential period yet for employer plan sponsors. What was once a narrow pipeline of treatments for ultra-rare pediatric conditions is rapidly diversifying into indications that affect working-age adults — including cancers, hemophilia, sickle cell disease (SCD), Duchenne muscular dystrophy (DMD), and emerging autoimmune and neurological targets.
The pipeline signals accelerating exposure. An 83% surge in pre-registration gene therapy programs was recorded in Q4 2024 alone. Therapeutically, the field is diversifying beyond oncology: more than half of newly initiated gene therapy trials in late 2024 targeted non-oncology indications.
On the policy front, the CMS (Centers for Medicare & Medicaid Services) Cell and Gene Therapy Access Model — outcomes-based agreements (OBAs) with manufacturers on behalf of Medicaid — reached 33 states plus Washington, D.C. as of early 2026. Private payers offer subscription-style programs at $0.99–$1.25 PMPM (per member per month).
As of Q4 2024, 4,238 therapies in development globally. Gene therapies comprise 49% of the pipeline. An 83% surge in pre-registration programs. Use as a quarterly calibration tool for emerging indications.
The most recent quarterly update from the American Society of Gene & Cell Therapy (ASGCT) tracking pipeline shifts, new approvals, and funding trends. Reference the most current issue when modeling future financial exposure.
Central archive for all ASGCT quarterly pipeline reports dating back to 2019. Each provides systematic updates on total therapies, new approvals, and indication-level breakdowns.
Global CGT spending reached $5.9B in 2023 (up 38% year-over-year), representing 62% U.S. share. Provides eight 'future scenarios' through 2035 for long-range benefits planning.
The Alliance for Regenerative Medicine (ARM) provides periodic Sector Snapshots with clinical milestones, commercial trends, and pipeline watchlists for the CGT sector.
FDA's CBER (Center for Biologics Evaluation and Research) communicated chemistry, manufacturing, and control (CMC) flexibility for CGTs. Signals accelerated development timelines — FDA expects 10–20 new approvals per year.
Analysis of three FDA draft guidances covering RMAT (Regenerative Medicine Advanced Therapy) designation, accelerated approval, and post-approval real-world data (RWD) methods. Post-approval guidance establishes registry-based evidence as the backbone for coverage decisions.
Reviews FDA's CGT regulatory actions in 2024: CBER's 14-guidance agenda, accelerated approval evolution, long-term follow-up (LTFU) reform, and the CoGenT (Collaboration on Gene Therapies) Global pilot for international convergence.
The Drug Information Association (DIA) analyzes growing use of accelerated approval for gene therapies. Accelerated approval means limited durability data at launch — increasing importance of OBAs (outcomes-based agreements) when making coverage decisions.
Rigorous analysis from the Institute for Clinical and Economic Review (ICER) and NEWDIGS (New Drug Development Paradigms initiative at Tufts) examining fair pricing, clinical uncertainty, and budget shock. Comprehensive menu of strategies for self-insured plan sponsors.
Peer-reviewed publication recommending stacking multiple payment strategies — reinsurance combined with milestone rebates and value-based contracts — as the most resilient approach for plan sponsors.
Identifies structural barriers to innovative payment model (IPM) uptake: payer preference for rebates, lack of interoperable data, and accounting complexity. Outlines what manufacturers can do to help employers build IPM capacity.
Proposes a stepwise framework from private market intermediation to public-private mandates. Key finding: patient churn (median job tenure 3–5 years) means employers pay for therapies whose value accrues to future insurers.
Models financial risk under different stop-loss contract structures. Four-year installment contracts may leave employers absorbing 58% of gross costs due to incurred/paid date mismatches. Proposes tripartite contracting arrangements.
Official CMS document establishing the CGT Access Model. The Centers for Medicare & Medicaid Services (CMS) outcome measures, rebate reconciliation, and data-sharing obligations are shaping commercial norms. Expanded to 33 states.
Concise explainer from Avalere Health translating the CMS CGT Access Model for payers: which terms are negotiated, what changes states must make, and implications for commercial CGT contracts.
Congressional Budget Office (CBO) analysis of coverage in Medicare, Medicaid, and commercial insurance for SCD gene therapies. Includes the NTAP (New Technology Add-on Payment) increase to 75% for SCD gene therapies in 2025.
The American Hospital Association (AHA) summarizes cooperative agreement funding for states joining the CGT Access Model. Signals infrastructure being built for operationalizing OBAs.
Landmark Employee Benefit Research Institute (EBRI) study: CGT utilization at 9.2 per 100,000 enrollees in 2022. Users represent less than 0.1% of enrollment but ~0.5% of total spending. Traditional cost-sharing tools have limited ability to reduce utilization.
Integrated Benefits Institute (IBI) survey: 33% of employers include CGTs in plans, 36% evaluating, 58% of non-adopters planning to add within 24 months. Employers with robust stop-loss are 2x more likely to implement CGT benefits.
Five structured action steps from the National Alliance of Healthcare Purchaser Coalitions (NAHPC). Includes eight vendor evaluation questions and a comparison of large employer strategies with adoption rates.
57% of plan sponsors with 500+ employees rank managing CGT costs among top pharmacy benefit priorities. 99–100% of commercial plan sponsors currently provide broad CGT coverage.
Downloadable checklist covering plan design, prior authorization, COE (Center of Excellence) selection, stop-loss coordination, genetic testing, and risk mitigation. Formatted for use with carriers, PBMs, and consultants.
Features AT&T's CGT risk management framework — three sequential questions: Is it right for the patient? Is it the right provider? Is it the right price? Proactive patient identification using claims algorithms is a recognized best practice.
Pipeline anticipation tools, benefit channel alignment (medical vs. pharmacy), COE design, and the GCIT® (Gene-Based, Cellular, and Other Innovative Therapies) program.
Annual report from the Center for International Blood and Marrow Transplant Research (CIBMTR) documenting utilization trends in HCT (hematopoietic cell transplantation) and CAR-T therapies. Includes patient-reported outcomes for the first time.
The U.S. Equal Employment Opportunity Commission (EEOC) explains GINA Title II protections: prohibition on requesting genetic information, exceptions for voluntary wellness programs, and enforcement guidance. Essential for employers implementing CGT programs with pre-treatment genetic testing.
Analyzes class-action litigation under GINA and GIPA (Illinois Genetic Information Privacy Act) for workplace programs that inadvertently solicit genetic information. Benefits and legal teams should review wellness and fitness-for-duty policies.
No resources match your search. Try a different keyword or filter.